Pfizer, the pharmaceutical giant, has projected a 24% take-up rate for COVID-19 shots in the United States. This estimate signifies approximately 82 million people receiving the vaccine.
- FDA Authorization: The US Food and Drug Administration (FDA) has authorized updated COVID-19 vaccines from Pfizer, BioNTech, Moderna, and is reviewing a third vaccine from Novavax. These authorizations come as the country gears up for an autumn vaccination campaign.
- Previous Revaccination Campaign: During the previous revaccination campaign, when most Americans had either previously contracted COVID-19 or received initial vaccination, only about 56.5 million people received booster shots. However, recent polling indicates that approximately half of Americans are interested in receiving an updated COVID-19 vaccine.
- Moderna’s Expectations: Rival pharmaceutical company Moderna anticipates the demand for COVID-19 shots to range between 50 million and 100 million doses during the autumn season.
- Decreased Demand: The demand for COVID-19 vaccines has significantly declined since their initial introduction in 2021. Pfizer announced plans for a cost-cutting program if vaccine demand continues to underperform expectations in the coming months.
- Cost-Cutting Measures: Pfizer’s CFO, David Denton, stated that the company will provide more details on cost-cutting measures in the second half of 2023. The aim is to align investments with the company’s revenue performance in the long term.
- Debates and Implications: Pfizer’s projection of a 24% uptake rate has sparked debates among experts, policymakers, and the general public. Some argue that the estimate is too low and could hinder efforts to achieve widespread immunity, while others express concerns about vaccine hesitancy and the potential for unused doses.